Prostate cancer is the second leading cause of cancer-related death among men in the United States (U.S.). No other authors report funding sources or potential conflicts of interest to disclose. This does not alter our adherence to PLOS ONE policies on sharing data and materials. has received research funding from Astellas, Clovis Oncology, Constellation, Amgen and Regeneron. receives research funding from GeneCentric Therapeutics, Genentech/Hoffman-La Roche, Bristol-Myers Squibb, and Merck. has received research funding from Merck, Roche/Genentech, Bristol-Myers Squibb, Astellas Pharma, Clovis Oncology, Inovio Pharmaceuticals, Mirati Therapeutics, Constellation Pharmaceuticals, Syndax, Incyte, Amgen, Regeneron, Arvinas, Seagen. reports a consulting or advisory role with AstraZeneca, Carevive Systems, Navigating Cancer, and Sivan.
reports a consulting role with ABK Biomedical. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper.įunding: The author(s) received no specific funding for this work.Ĭompeting interests: A.H.K. Received: JanuAccepted: ApPublished: June 21, 2021Ĭopyright: © 2021 Kim et al. PLoS ONE 16(6):Įditor: Ramon Andrade De Mello, Nine of July University (UNINOVE), BRAZIL
(2021) A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Citation: Kim SI, Szeto AH, Morgan KP, Brower B, Dunn MW, Khandani AH, et al.
0 kommentar(er)
